ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences announced positive Phase II(b) clinical trial results for Saroglitazar Mg in MASH. The global study successfully met its primary endpoint of resolution of steatohepatitis.
Zydus Lifesciences received final USFDA approval for Ascorbic Acid Injection with 180-day exclusivity. The reference brand product had annual US sales of approximately USD 11.6 million.
Zydus Lifesciences' subsidiary, Sentynl Therapeutics, signed an option and license agreement with Mereo BioPharma for alvelestat. The deal includes upfront and R&D payments totaling 380 Crore.